Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Lauro M Takeuchi"'
Autor:
Raul A Dulce, Rosemeire M Kanashiro-Takeuchi, Lauro M Takeuchi, Alessandro G Salerno, Amarylis C B A Wanschel, Shathiyah Kulandavelu, Wayne Balkan, Marilia S S R Zuttion, Renzhi Cai, Andrew V Schally, Joshua M Hare
Publikováno v:
Cardiovascular Research. 118:3586-3601
Aims To test the hypothesis that the activation of the growth hormone-releasing hormone (GHRH) receptor signalling pathway within the myocardium both prevents and reverses diastolic dysfunction and pathophysiologic features consistent with heart fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc2a2a98eaa511bd53a75be1724a6b4c
https://doi.org/10.1093/cvr/cvac098
https://doi.org/10.1093/cvr/cvac098
Autor:
Angela C Rieger, Bryon A Tompkins, Makoto Natsumeda, Victoria Florea, Monisha N Banerjee, Jose Rodriguez, Marcos Rosado, Valeria Porras, Krystalenia Valasaki, Lauro M Takeuchi, Kevin Collon, Sohil Desai, Michael A Bellio, Aisha Khan, Nilesh D Kashikar, Ana Marie Landin, Darrell V Hardin, Daniel A Rodriguez, Wayne Balkan, Joshua M Hare, Ivonne Hernandez Schulman
Publikováno v:
Stem Cells Translational Medicine. 11:59-72
Background Left ventricular hypertrophy and heart failure with preserved ejection fraction (HFpEF) are primary manifestations of the cardiorenal syndrome in patients with chronic kidney disease (CKD). Therapies that improve morbidity and mortality in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a63346367e949226ebab651b948d508
https://doi.org/10.1093/stcltm/szab004
https://doi.org/10.1093/stcltm/szab004
Autor:
Rosemeire M. Kanashiro-Takeuchi, Lauro M. Takeuchi, Raul A. Dulce, Katarzyna Kazmierczak, Wayne Balkan, Renzhi Cai, Wei Sha, Andrew V. Schally, Joshua M. Hare
Heart failure (HF) with preserved ejection fraction (HFpEF) represents a major unmet medical need owing to its diverse pathophysiology and lack of effective therapies. Potent synthetic, agonists (MR-356 and MR409) of growth hormone-releasing hormone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf5eb5724af07ef228e142b868993d34
https://doi.org/10.1101/2022.09.18.508429
https://doi.org/10.1101/2022.09.18.508429
Autor:
Michael A. Bellio, Shathiyah Kulandavelu, Wayne Balkan, Karen C. Young, Lauro M Takeuchi, Yee-Shuan Lee, Rosemeire M. Kanashiro-Takeuchi, Aisha Khan, Joshua M. Hare
Publikováno v:
The journal of cardiovascular aging
Introduction: Cardiovascular disease and myocardial infarction are leading causes of morbidity and mortality in aged populations. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) are under evaluation as a therapeutic option for the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::711978d776f546f65368cfb2f2f8e874
https://doi.org/10.20517/jca.2021.21
https://doi.org/10.20517/jca.2021.21
Autor:
Rosemeire M. Kanashiro-Takeuchi, Katarzyna Kazmierczak, Jingsheng Liang, Lauro M. Takeuchi, Yoel H. Sitbon, Danuta Szczesna-Cordary
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 24; Pages: 15589
In this study, we aimed to investigate whether short-term and low-dose treatment with hydroxychloroquine (HCQ), an antimalarial drug, can modulate heart function in a preclinical model of dilated cardiomyopathy (DCM) expressing the D94A mutation in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e94ed9e0fbe95e23731fe78bd14de0
https://doi.org/10.3390/ijms232415589
https://doi.org/10.3390/ijms232415589
Autor:
Raul A, Dulce, Rosemeire M, Kanashiro-Takeuchi, Lauro M, Takeuchi, Alessandro G, Salerno, Amarylis C B A, Wanschel, Shathiyah, Kulandavelu, Wayne, Balkan, Marilia S S R, Zuttion, Renzhi, Cai, Andrew V, Schally, Joshua M, Hare
Publikováno v:
Cardiovasc Res
To test the hypothesis that the activation of the growth hormone-releasing hormone (GHRH) receptor signaling pathway within the myocardium both prevents and reverses diastolic dysfunction and pathophysiologic features consistent with heart failure wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3696cf370eb676bdb14e37efe0660390
https://pubmed.ncbi.nlm.nih.gov/35704032
https://pubmed.ncbi.nlm.nih.gov/35704032
Autor:
Rosemeire M. Kanashiro-Takeuchi, Alessandro Salerno, Andrew V. Schally, Amarylis C. B. A. Wanschel, Peter Buchwald, Joshua M. Hare, Ivonne Hernandez Schulman, Raul A Dulce, Victoria Florea, Marcos Rosado, Darren Turner, Luiza Bagno, Wayne Balkan, Angela C. Rieger, Jose Rodriguez, Lauro M Takeuchi
Publikováno v:
Proc Natl Acad Sci U S A
Therapies for heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone-releasing hormone agonists (GHRH-As) have salutary effects in ischemic and nonischemic heart failure animal models. Accordingly, we hypothesized that GHR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e0f16ff5f30c21f6d4e44c06d044b9
https://pubmed.ncbi.nlm.nih.gov/33468654
https://pubmed.ncbi.nlm.nih.gov/33468654
Autor:
Lauro M Takeuchi, Rosemeire M. Kanashiro-Takeuchi, Raul A Dulce, Renzhi Cai, Andrew V. Schally, Joshua M. Hare, Wayne Balkan, Alessandro Salerno
Publikováno v:
Circulation. 142
Introduction: Heart failure with preserved ejection fraction (HFpEF) accounts for ~50% of heart failure cases and is characterized by impaired relaxation, ventricular stiffening and fibrosis. Growth hormone releasing hormone-agonists (GHRH-As) reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9830be1406738ded6e63d95e6e8a2e16
https://doi.org/10.1161/circ.142.suppl_3.15998
https://doi.org/10.1161/circ.142.suppl_3.15998
Autor:
Lauro M Takeuchi, Angela C Castellanos, Monisha N. Banerjee, Aisha Khan, Wayne Balkan, Daniel A. Rodriguez, Ivonne Hernandez Schulman, Victoria Florea, Michell Bellio, Joshua M. Hare, Jose Rodriguez, Darrell Hardin, Marcos Rosado, Bryon A. Tompkins, Makoto Natsumeda, Kristalenia Valasaki, Sohil S. Desai
Publikováno v:
Circulation Research. 127
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition involving multiple comorbidities. Phenotypic classification of HFpEF associated with chronic kidney disease (CKD) manifests worse outcomes, compared to ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab1a3776a343a8515c5f2c23698afd79
https://doi.org/10.1161/res.127.suppl_1.471
https://doi.org/10.1161/res.127.suppl_1.471
Autor:
Victoria Florea, Angela C. Rieger, Jose Rodriguez, Raul A Dulce, Marcos Rosado, Luiza Bagno, Alessandro Salerno, Lauro M Takeuchi, Joshua M. Hare, Andrew V. Schally, Wayne Balkan, Ivonne Hernandez Schulman, Darren Turner
BackgroundTherapies that improve morbidity and mortality in heart failure with preserved ejection fraction (HFpEF) are lacking. Growth hormone releasing hormone analogues (GHRH-A) reverse fibrosis and improve cardiac function in ischemic and non-isch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::031b195935d8c32ffd2eb30ac11f818c
https://doi.org/10.1101/2020.05.30.111476
https://doi.org/10.1101/2020.05.30.111476